Citigroup
KLRS

Citigroup’s Kalaris Therapeutics KLRS Stock Holding History

Citigroup’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,703
Closed -$50.2K – 6388
2026
Q1 		$50.2K Buy
8,703
+8,702
+870,200% +$77.2K ﹤0.01% 4528
2025
Q4 		$8 Hold
1
– – ﹤0.01% 5830
2025
Q3 		$6 Buy
+1
New +$3 ﹤0.01% 5982
2025
Q1 		– Sell
-7
Closed -$66 – 6065
2024
Q4 		$66 Sell
7
-36
-84% -$545 ﹤0.01% 5706
2024
Q3 		$800 Sell
43
-289
-87% -$5.05K ﹤0.01% 5458
2024
Q2 		$5.53K Sell
332
-122
-27% -$2.15K ﹤0.01% 5246
2024
Q1 		$7.89K Buy
454
+129
+40% +$2.1K ﹤0.01% 5251
2023
Q4 		$5.08K Buy
325
+259
+392% +$10.2K ﹤0.01% 5331
2023
Q3 		$3.28K Sell
66
-608
-90% -$41.4K ﹤0.01% 4834
2023
Q2 		$52.7K Buy
674
+563
+507% +$53.5K ﹤0.01% 4612
2023
Q1 		$10.1K Sell
111
-2
-2% -$255 ﹤0.01% 4726
2022
Q4 		$13.3K Buy
113
+1
+0.9% +$170 ﹤0.01% 4740
2022
Q3 		$20K Sell
112
-167
-60% -$26K ﹤0.01% 4754
2022
Q2 		$25K Buy
279
+17
+6% +$1.78K ﹤0.01% 4879
2022
Q1 		$41K Sell
262
-2,234
-90% -$446K ﹤0.01% 4817
2021
Q4 		$743K Buy
2,496
+1,100
+79% +$510K ﹤0.01% 3523
2021
Q3 		$804K Sell
1,396
-3,497
-71% -$1.62M ﹤0.01% 3252
2021
Q2 		$2.22M Buy
4,893
+816
+20% +$421K ﹤0.01% 2590
2021
Q1 		$2.19M Buy
4,077
+3,812
+1,438% +$3.2M ﹤0.01% 2429
2020
Q4 		$234K Buy
265
+228
+616% +$175K ﹤0.01% 4875
2020
Q3 		$24K Buy
+37
New +$25.3K ﹤0.01% 6064

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's KLRS Position: Q2 2026 in Review

Citigroup sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 8,703 shares — an estimated $50.2K sold.

Citigroup first reported a position in KLRS in Q3 2020 and held it in 21 quarters. The position peaked at $2.22M in Q2 2021. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Citigroup reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 8,703 Kalaris Therapeutics shares in Q2 2026, an estimated $50.2K.
  • Citigroup first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 21 quarters.
  • Citigroup's Kalaris Therapeutics position peaked at $2.22M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.